Literature DB >> 25849298

Electromagnetic navigation-guided TBNA vs conventional TBNA in the diagnosis of mediastinal lymphadenopathy.

Özlem E Diken1, Demet Karnak, Aydın Çiledağ, Koray Ceyhan, Çetin Atasoy, Serdar Akyar, Oya Kayacan.   

Abstract

OBJECTIVES: Conventional transbronchial needle aspiration (C-TBNA) is a safe method for the diagnosis of hilar and mediastinal lymphadenopathy (MLN). However, diagnostic yield of this technique varies considerably. Electromagnetic navigation bronchoscopy (ENB) is a new technology to increase the diagnostic yield of flexible bronchoscopy for the peripheral lung lesions and MLN. The aim of this prospective study was to compare the diagnostic and sampling success of ENB-guided TBNA (ENB-TBNA) in comparison with C-TBNA while dealing with MLN.
METHODS: Consecutive patients with MLN were randomized into two groups - C-TBNA and ENB-TBNA - using a computer-based number shuffling system to avoid recruitment bias. Procedures were performed in usual fashion, published previously.
RESULTS: Ninety-four cases (M/F: 45/49) with a total of 145 stations of MLN were enrolled in the study. In 44 patients, 81 stations were sampled by ENB-TBNA, and in 50 patients 64 stations by C-TBNA. The mean size of MLN in study subjects was 17.56 ± 6.25 mm. The sampling success was significantly higher in ENB-TBNA group (82.7%) compared with C-TBNA group (51.6%) (P < 0.005). Defined by histopathological result, the diagnostic yield in ENB-TBNA was 72.8%, and 42.2% with C-TBNA (P < 0.005). For subcarinal localization, sampling or diagnostic success was higher in ENB-TBNA than that of C-TBNA (P < 0.05). Based on the size of the MLN ≤15 mm or >15 mm, the sampling success of ENB-TBNA was also significantly higher than C-TBNA in both subgroups (P < 0.005 and P < 0.005, respectively). No serious complication was observed.
CONCLUSION: In this study comparing ENB-TBNA and C-TBNA, the sampling and diagnostic success of ENB-TBNA was found to be superior while dealing with MLN, in all categories studied.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  bronchoscopy; electromagnetic navigation; electromagnetic navigation bronchoscopy; flexible bronchoscopy; mediastinal lymph node; transbronchial needle aspiration

Mesh:

Year:  2014        PMID: 25849298     DOI: 10.1111/crj.12126

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

Review 1.  The role of bronchoscopy in the diagnosis of airway disease.

Authors:  Tyler J Paradis; Jennifer Dixon; Brandon H Tieu
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 2.  Insight into the differences in classification of mediastinal and hilar lymph nodes between Wang's lymph node map and the International Association for the Study of Lung Cancer lymph node map.

Authors:  Ya-Qing Li; Ko-Pen Wang; Su-Qin Ben
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 3.  Navigational transbronchial needle aspiration, percutaneous needle aspiration and its future.

Authors:  Sixto Arias; Lonny Yarmus; A Christine Argento
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

4.  A multimodal image guiding system for Navigated Ultrasound Bronchoscopy (EBUS): A human feasibility study.

Authors:  Hanne Sorger; Erlend Fagertun Hofstad; Tore Amundsen; Thomas Langø; Janne Beate Lervik Bakeng; Håkon Olav Leira
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 5.  Design of a prospective, multicenter, global, cohort study of electromagnetic navigation bronchoscopy.

Authors:  Erik E Folch; Mark R Bowling; Thomas R Gildea; Kristin L Hood; Septimiu D Murgu; Eric M Toloza; Momen M Wahidi; Terence Williams; Sandeep J Khandhar
Journal:  BMC Pulm Med       Date:  2016-04-26       Impact factor: 3.317

Review 6.  Application of Electromagnetic Navigation Bronchoscopy in the early diagnosis and treatment of lung cancer: a narrative review.

Authors:  Wen-Hui Yang; Tian-Qi Xu; Yan Zhang; Lin Jiang; Jian Zhang
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.